

Nivolumab Biosimilar - Research Grade ICH4009

Product Information

| | |
|-----------------------------|---|
| Catalog Number: | ICH4009 |
| Product: | Low endotoxin, biosimilar antibody |
| Target: | PD-1 |
| Isotype: | IgG4 kappa |
| Other names: | Programmed cell death protein 1, Pdc1, CD279 |
| Host: | Humanized |
| Species Reactivity: | Human |
| Specificity: | Detects human PD-1. This non-therapeutic antibody uses the same sequence as the therapeutic antibody Nivolumab. |
| Purification method: | This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype. |
| Concentration: | 1.0 - 5.0 mg/ml |
| Formulation: | Phosphate buffered saline (PBS) pH 7.2, with no carrier protein, potassium or preservatives added. BSA and Azide free. |
| Purity: | >95% by SDS-PAGE and HPLC |
| Endotoxin: | ≤ 0.75 EU/mg as determined by the LAL method |
| Storage: | Stable for at least one week when stored sterile at 2-8°C. For long term storage aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles. |

Background:

Nivolumab biosimilar is a human monoclonal antibody that blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2. Nivolumab is an IgG4 kappa immunoglobulin that has a calculated molecular mass of 146 kDa. It is expressed in a recombinant Chinese Hamster Ovary (CHO) cell line.